## **CENTRAL FAX CENTER**

OCT 132006 PTO/SB/21 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031

Under the Par	perwork Reduction Act of 1995	no parson					J.S. DEPARTMENT OF COMMERCE displays a valid OMB control number.
		_	Application Number	10/526,02			
TR	ANSMITTAL		Filing Date	Septembe	r 20, 2005	5	
	FORM		First Named Inventor	Yousef et	g).		
			Art Unit	1642			
IM ha wood the	all correspondence after initial (	Week	Examiner Name	S. Aeder,	PhD		
		ini (B)	Attorney Docket Number	11757.800	ISWO		
Total Number of	Pages in This Submission			1111001			
		ENC	LOSURES (Check t	sii that appi	r)		
☐ F6	smiltal Form ee Attached		Drawing(s)			Appea of App	I Communication to TC  I Communication to Board eals and Interferences  I Communication to TC.
Extension Express A Information Certified ( Document Reply to I Incomplet	fter Final  ffdavite/declaration(e)  of Time Request  Abandonment Request  on Disclosure Statement  Copy of Priority		Petition Petition to Convert to a Provisional Application Power of Attorney, Revoca Change of Correspondence Ferminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on	Address		(Appea Propri	il Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please Identify
_	SIGNA	TURE C	OF APPLICANT, ATT	ORNEY.	OR AG	ENT	
Firm Name	Howson and Howson						
Signature	May E. Ba	<u>l</u>					
Printed name	Mary E. Bak						
Date	10-13-2006			Reg. No.	31,215	5	
	ĊI	ERTIFIC	CATE OF TRANSMIS	SION/MA	ILING		
sufficient postage the date shown b	e as first class mail in an env	eing facsi relope ad	mile transmitted to the USi dressed to: Commissioner	PTO or depo- for Patents,	sited will P.O. Box	the Un 1450, /	ited States Postal Service with Alexandria, VA 22313-1450 on
Signature	3	0	ي				
Typed or printed	name Summer Uchin					Date	10-13-2006
~							/

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select aption 2.

# RECEIVED CENTRAL FAX CENTER

OCT 1 3 2006

11757.80USWO

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/526,029

Confirmation No.: 5441

Applicant

: Yousef et al.

Filed

: September 20, 2005

TC/A.U.

: 1642

Examiner

: S. Aeder, PhD

Customer No.

: 00270

Title

: METHODS FOR DETECTING BREAST AND OVARIAN

CANCER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### **AMENDMENT AND RESPONSE UNDER 35 USC § 121**

Sir:

This paper is in timely response to the outstanding Office Action dated September 15, 2006 and issued for restriction purposes.

Elections being on page 2.

Amendments to the Claims begin on page 3.

Remarks/Arguments begin on page 7.

CERTIFICATE OF	TRANSMISSION/MAILING
I hereby certify that this correspondence is being facsimi	le transmitted to or deposited with the United States Postal
	to Commissioner for Patents, P.O. Box 1450 Alexandria, VA
	the state of the s
22313-1450 on the date shown below:	

11757.80USWO

#### **ELECTIONS**

In response to the outstanding restriction requirement, Applicants hereby elect the claims of Group I, i.e., claims 3, 5, 6, 9-12, 26, and 28-33, drawn to a method for detecting a subject for breast cancer, a method of screening a subject for breast cancer, a method for monitoring the progression of breast cancer, and a kit comprising reagents that specifically bind kallikrein 5.